Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer - a podcast by Clinical Care Options
from 2021-07-20T22:00
In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:
- Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223
- Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial
- Ongoing trials evaluating radionuclides in combination with other agents in metastatic CRPC
Presenters:
Chris Parker, MD
Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Bertrand Tombal, MD, PhD
Professor of Urology
Institut de Recherche Clinique (IRC)
Cliniques universitaires Saint-Luc
Chairman
Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium
Link to full program, including downloadable slides:
https://bit.ly/36IEnNE
Further episodes of CCO Oncology Podcast
Further podcasts by Clinical Care Options
Website of Clinical Care Options